Phase II Study of 5-Fluorouracil, Oxaliplatin plus Dasatinib (FOLFOX-D) in First-Line Metastatic Pancreatic Adenocarcinoma

CONCLUSION: The addition of dasatinib did not appear to add incremental clinical benefit to FOLFOX in untreated mPC patients.PMID:34101295 | DOI:10.1002/onco.13853
Source: The Oncologist - Category: Cancer & Oncology Authors: Source Type: research